drugset / Trial / NCT00593645
Clofarabine, Cytarabine, and Thymoglobulin for Allogeneic Transplantation
NaSingle-groupOpen-labelTreatment
Summary
This study will test the combination of clofarabine, cytarabine, and thymoglobulin as a non-myeloablative conditioning regimen for patients with myelodysplastic syndromes or acute myeloid leukemia undergoing allogeneic stem cell transplant.
Timeline
- Start
- 2007-11
- Primary completion
- 2008-12
- Completion
- 2009-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Clofarabine | Other / unclassified | 40 mg/m2 | Intravenous |
| Subject | Cytarabine | Small molecule | 1 g | Intravenous |
| Subject | Thymoglobulin | Protein / enzyme biologic | 2.5 mg/kg | Intravenous |